Molnupiravir Vs. Remdesivir: What is the Difference?
Introduction In the battle against viral infections, antiviral drugs play a crucial role in reducing the severity and spread of the disease. Since the outbreak of the COVID-19 pandemic, several antiviral medications have been repurposed and developed to combat the SARS-CoV-2 virus responsible for the disease. Among these drugs, Molnupiravir and Remdesivir have emerged as prominent contenders, both showing promise in treating COVID-19 patients. In this article, we will explore the key differences between Molnupiravir and Remdesivir, including their mechanisms of action, clinical efficacy, safety profiles, and potential implications for COVID-19 treatment. Molnupiravir: An Overview Molnupiravir, also known as MK-4482, is an oral antiviral drug developed by Merck & Co. Inc. and Ridgeback Biotherapeutics. It belongs to a class of antiviral agents known as nucleoside analogs. Molnupiravir is designed to specifically target RNA viruses, including SARS-CoV-2, the virus responsible f...